IP Library › Granted Patent US 9,939,449
Granted Patent B2
US 9,939,449 · App. 13/983,114 · Granted Apr 10, 2018

Diagnostic and therapeutic methods and products related to anxiety disorders

Inventors: Victor May (Essex, VT); Kerry J. Ressler (Atlanta, GA); Sayamwong E. Hammack (Essex Junction, VT); Donna Toufexis (So. Burlington, VT); Karen M. Braas (Essex, VT)
Assignee: The University of Vermont and State Agricultural College
G01N33/6893C12Q1/6883C12Q2600/112C12Q2600/154C12Q2600/156C12Q2600/158G01N2333/5757G01N2800/301
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,939,449
App. No.
13/983,114
Granted
Apr 10, 2018
Kind
B2
Abstract

The present disclosure provides methods for diagnosing and treating anxiety disorders in female subjects. Diagnosis and treatment of such anxiety disorders are based, in part, on an analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in tissue collected from female subjects.

Claims (11)

1. A method for diagnosing and treating post traumatic stress disorder (PTSD) in a female human, comprising:

a) analyzing pituitary adenylate cyclase-activating polypeptide (PACAP) expression levels in a tissue sample collected from a female human;

b) diagnosing PTSD in the female human having elevated tissue PACAP expression levels as compared to a control tissue sample obtained from a subject who does not have PTSD; and

c) administering to the female human diagnosed in (b) a therapeutically effective amount of an antibody that binds specifically to an epitope at the carboxy-terminal end of PACAP.

2. The method of claim 1 , wherein the female human exhibits at least one endophenotype of PTSD.

3. The method of claim 2 , wherein the at least one PTSD endophenotype is selected from the group consisting of: intrusive re-experiencing, avoidance, hyperarousal, and fear discrimination.

4. The method of claim 1 , wherein the PACAP expression levels comprise PACAP-38 and PACAP-27 expression levels.

5. The method of claim 1 , wherein the PACAP expression levels comprise PACAP-38 expression levels.

6. The method of claim 1 , wherein the analyzing of PACAP expression levels in the tissue sample is by radioimmunoassay.

7. The method of claim 1 , wherein the tissue sample is selected from the group consisting of blood, serum, plasma, and cerebrospinal fluid (CSF).

8. The method of claim 7 , wherein the tissue sample is blood.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME TO UNIVERSITY OF VERMONT ANDSTATE AGRICULTURAL COLLEGE PREVIOUSLY RECORDED ON REEL 38134 FRAME 110. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 5, 2026
From: MAY, VICTOR; HAMMACK, SAYAMWONG E.; TOUFEXIS, DONNA; BRAAS, KAREN M.
To: UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
Reel/Frame 074197/0641 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2016
From: MAY, VICTOR; HAMMACK, SAYAMWONG E.; TOUFEXIS, DONNA; BRAAS, KAREN M.
To: THE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
Reel/Frame 038134/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2016
From: RESSLER, KERRY J.; HOWARD HUGHES MEDICAL INSTITUTE
To: EMORY UNIVERSITY
Reel/Frame 038134/0142 →
APPOINTMENT OF INVESTIGATOR AS AGENT Recorded Mar 30, 2016
From: HOWARD HUGHES MEDICAL INSTITUTE
To: RESSLER, KERRY
Reel/Frame 038300/0492 →
Continuity (2)
Provisional Application 61483380 · Feb 1, 2011
Related Publication 20150309050A1 · Oct 29, 2015